Research Updates in Hematology
Special Issue Editor
Interests: hematologic malignancies; thrombosis; complement; cellular therapy; lymphoma; myeloma; COVID-19
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent decades, many advances have been made to better understand the pathogenetic mechanisms of hematological disorders, malignant and benign, leading to the development of novel diagnostic methods and therapeutic agents. Personalized and targeted therapeutics have revolutionized the management of these patients, especially in the field of malignant hematology. The introduction of chimeric antigen receptor-T (CAR-T) immunotherapy and bispecific antibodies in everyday clinical practice is now a fundamental part of relapsed/refractory lymphoma and multiple myeloma patient management. Nevertheless, complications and novel toxicities have arisen in the post-infusion period and more data regarding their pathogenesis are crucial. Additionally, allogeneic and autologous hematopoietic cell transplantation (HCT) are considered the only curable therapeutic interventions for some patients. Despite the advances made, the mortality and morbidity that HCT recipients experience, especially after allogeneic HCT, is still high.
Beyond hematological malignancies, several achievements have been made in the field of hemoglobinopathies and congenital bleeding disorders. The recent official approval of gene therapy for hemophilia B and sickle cell disease are considered therapeutic landmarks for these patient populations. However, more real-world data concerning this topic are of paramount importance. Moreover, endothelial injury, low-grade inflammation, and dysregulation of coagulation cascade are implicated in the development of the above-described disorders and several other clinical hematological entities. The recognition of common pathophysiological mechanisms between hematological and other disorders, such as antiphospholipid syndrome, is of paramount importance.
This Special Issue will provide new insights into the ongoing research into hematological diseases. The Special Issue is supervised by Dr. Eleni Gavriilaki, Mr. Nikolaos Kotsiou, and Dr. Paschalis Evangelidis.
More specifically, the aim is to collect original studies and comprehensive reviews on this research topic. Topics may include (but are not limited to) the study of research updates in hematology in the following areas: antiphospholipid syndrome, complement, endothelium, hemoglobinopathies, hemophilia, leukemias, lymphomas, multiple myeloma, pediatric hematology, and thrombosis.
Dr. Eleni Gavriilaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antiphospholipid syndrome
- complement
- endothelium
- hemoglobinopathies
- hemophilia
- leukemias
- lymphomas
- multiple myeloma
- pediatric hematology
- thrombosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
